Top 10 Manufacturers of Pharmaceutical Intermediate CAS No. 85006-31-1 in 2025

Understanding (S)-(-)-2-(Diphenylhydroxymethyl)pyrrolidine (CAS No. 85006-31-1)

CAS No. 85006-31-1, known as (S)-(-)-2-(Diphenylhydroxymethyl)pyrrolidine, is a chiral compound widely used as a pharmaceutical intermediate in the synthesis of various active pharmaceutical ingredients (APIs). Its rigid chiral center and secondary amine group make it an essential building block in asymmetric synthesis and stereoselective drug development.

This compound is often used in the production of:

• HIV protease inhibitors

• Antiviral drugs

• Central nervous system (CNS) agents

• Beta-blockers and cardiovascular therapeutics

Its high enantiomeric purity is crucial for ensuring the safety, efficacy, and regulatory compliance of the final pharmaceutical product.

Importance of CAS No. 85006-31-1 in Drug Manufacturing

Chiral Building Block:

The (S)-configuration is critical in synthesizing enantiomerically pure APIs, which improves drug-target interaction and reduces side effects.

Widely Used in Antiviral Drug Synthesis:

It plays a key role in the production of protease inhibitors, particularly for HIV and HCV therapies.

Optimized for CNS and Cardiovascular Agents:

It enables the development of selective, receptor-specific CNS drugs and beta-blockers with minimized off-target effects.

Regulatory Acceptance:

Manufacturers must meet stringent FDA and EMA requirements, making this intermediate a high-value compound in cGMP-compliant production.

Customizable for Contract Synthesis:

Its structural features make it adaptable for contract development and manufacturing organizations (CDMOs) focused on tailored drug development.

Top 10 Manufacturers of CAS No. 85006-31-1

1. Lonza Group

• Location: Basel, Switzerland

• Overview: Lonza specializes in chiral intermediates for antiviral and oncology drugs. Their advanced synthesis and purification methods ensure enantiomeric excess and batch consistency.

• Specialty: High-purity stereoselective intermediates for regulated markets.

2. BASF

• Location: Ludwigshafen, Germany

• Overview: BASF supports API manufacturers with building blocks like CAS 85006-31-1, produced under stringent EU standards and optimized for scalability.

• Specialty: Industrial-scale chiral chemistry for cardiovascular and antiviral drugs.

3. Eastfine

• Location: Changzhou City, Jiangsu Province, China

• Overview: Eastfine manufactures enantiomerically pure pharmaceutical intermediates such as CAS 85006-31-1, with full documentation and international export compliance.

• Specialty: Chiral compound synthesis with focus on HIV and CNS drug intermediates.

4. Evonik Industries

• Location: Essen, Germany

• Overview: Evonik offers custom synthesis and contract manufacturing of complex intermediates, including chiral pyrrolidines.

• Specialty: Integrated services for early-stage development to commercial scale.

5. Olon S.p.A.

• Location: Milan, Italy

• Overview: Olon manufactures a wide range of advanced intermediates and APIs under cGMP conditions, including compounds for antiviral and neuroactive drugs.

• Specialty: EU-compliant manufacturing and scale-up for regulated markets.

6. Ash Stevens (Cambrex Company)

• Location: Riverview, Michigan, USA

• Overview: Ash Stevens specializes in high-potency API and chiral intermediate manufacturing, supporting pharma companies with small-to-mid scale quantities.

• Specialty: FDA-inspected facility for high-purity chiral synthesis.

7. Dishman Carbogen Amcis

• Location: Ahmedabad, India / Switzerland

• Overview: Dishman produces pharmaceutical intermediates and APIs with strong expertise in chiral synthesis and contract development.

• Specialty: Dual-site manufacturing and regulatory experience across the US, EU, and Japan.

8. Pharmblock Sciences

• Location: Exton, Pennsylvania, USA

• Overview: Pharmblock supplies building blocks for pharmaceutical R&D and clinical production, with an emphasis on complex and chiral molecules.

• Specialty: Rapid-response synthesis and custom route development.

9. Seqens Group

• Location: Ecully, France

• Overview: Seqens develops and manufactures pharmaceutical intermediates, including advanced chiral compounds, under strict GMP conditions.

• Specialty: Regulatory documentation and global supply chain security.

10. Ajinomoto Bio-Pharma Services

• Location: San Diego, USA / Tokyo, Japan

• Overview: Ajinomoto offers contract development for APIs and intermediates, focusing on biocatalysis and enantioselective synthesis.

• Specialty: Fermentation-derived chiral intermediates and enzymatic resolution.

Trends in the Pharmaceutical Intermediates Market

Rising Demand for Chiral Purity:

The pharmaceutical industry increasingly demands enantiomerically pure intermediates like CAS 85006-31-1 to meet FDA and EMA expectations for stereospecific drugs.

Growth of Antiviral Drug Pipelines:

With ongoing innovation in HIV, hepatitis, and respiratory virus therapies, chiral intermediates for protease inhibitors are gaining importance.

CDMO Expansion:

More companies are outsourcing the manufacture of complex intermediates to trusted CDMOs, creating opportunities for companies like Eastfine, Dishman, and Cambrex.

Custom Route Development:

Custom synthesis for difficult-to-scale chiral compounds is becoming a competitive differentiator among intermediate manufacturers.

Sustainability and Green Chemistry:

Enantioselective synthesis using biocatalysis or asymmetric hydrogenation is growing, reducing waste and improving atom economy.

Conclusion

CAS No. 85006-31-1 plays a critical role in the synthesis of advanced APIs, especially in the antiviral, cardiovascular, and CNS drug classes. With global manufacturers like Lonza, BASF, and Eastfine leading the way, the compound is produced under tight quality controls and regulatory standards to support both innovator and generic pipelines.

As demand rises for stereochemically precise pharmaceuticals, manufacturers of chiral intermediates like this one will continue to shape the future of medicine.